Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression

  • Ray Wang
  • , Peter Horwich
  • , Vlad C. Sandulache
  • , David J. Hernandez
  • , Joshua Hornig
  • , Evan M. Graboyes
  • , Nelson E. Liou
  • , Judith Skoner
  • , Angela D. Haskins
  • , Viran Ranasinghe
  • , Terry A. Day
  • , Erich M. Sturgis
  • , Andrew T. Huang

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Patients on chronic pharmacologic immunosuppressive therapy are at increased risk of wound infection and complications after surgery. There is a paucity of data examining perioperative complications after microvascular free tissue transfer (MVFTT) reconstruction of the head and neck in this patient population. Methods: Retrospective cohort study performed at two tertiary referral centers between August 2016 and May 2020. Results: Nine hundred and seventy-nine patients underwent MVFTT during the study period; of these 47 (5%) patients were taking chronic immunosuppressive medications. The most common indications for immunosuppression were solid organ transplant and autoimmune disease. Fourteen (30%) patients had surgical complications within 30 days of surgery: 8 (17%) wound dehiscences, 6 (12%) hematomas, and 2 (4%) surgical site infections. There was one total and one partial flap failure with a 30-day reoperation rate of 4%. Conclusions: MVFTT of the head and neck appears to be safe in patients on chronic pharmacologic immunosuppression.

Original languageEnglish (US)
Pages (from-to)1520-1527
Number of pages8
JournalHead and Neck
Volume44
Issue number7
DOIs
StatePublished - Jul 2022
Externally publishedYes

Keywords

  • free flap
  • head and neck cancer
  • immunosuppression
  • microvascular surgery
  • organ transplant

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression'. Together they form a unique fingerprint.

Cite this